Efficacy News and Research

RSS

Precision Biologics reports findings from Phase I/IIA study of NPC-1C at ASCO meeting

Precision Biologics, in collaboration with investigators from Duke University, has been selected to present an abstract of findings from its Phase 2 clinical trial at the Annual Meeting of the American Society of Clinical Oncology.

4 Jun 2013

Amgen reports encouraging results from talimogene laherparepvec phase 3 study in patients with metastatic melanoma

Amgen today announced detailed results from a pivotal Phase 3 trial evaluating talimogene laherparepvec in patients with unresected stage IIIB, IIIC or IV melanoma compared to granulocyte-macrophage colony-stimulating factor (GM-CSF).

3 Jun 2013

Phase I/II study shows safety and efficacy of VB-111 in patients with rGBM

VBL Therapeutics, a clinical-stage biotechnology company committed to the development of novel treatments for immune-inflammatory diseases and cancer, today announced clinical data demonstrating the utility of VB-111's in targeted cancer treatment.

3 Jun 2013

Experts to discuss on resuscitation efforts at Euroanaesthesia

One of the most difficult moments faced by anaesthetists and other healthcare staff is when to carry on attempts to resuscitate a person, and when those efforts should reasonably stop. This dilemma is the subject of a session at Euroanaesthesia, the annual congress of the European Society of Anaesthesiology.

3 Jun 2013

Human tumors with MET amplification respond to MET inhibitor drugs

A subset of colorectal cancers responds to anti-epidermal growth factor receptor (anti-EGFR) therapies, but develops resistance within months. Among cancers that develop resistance to anti-EGFR therapy, some showed overexpression of a gene called MET, according to a study published in the June issue of Cancer Discovery, a journal of the American Association for Cancer Research.

3 Jun 2013

RPCI, Jasco Pharmaceuticals partner to advance development of cancer therapy

A new partnership, first of its kind for both organizations, will see Roswell Park Cancer Institute and Jasco Pharmaceuticals, LLC collaborating to advance development of an investigational pharmacological therapy that shows promise for treating both solid-tumor cancers and hematologic malignancies.

1 Jun 2013

New drug for multiple myeloma could be available within next few months in Europe

The International Myeloma Foundation - improving the quality of life of myeloma patients while working toward prevention and a cure - today said the newest drug for treating multiple myeloma could be available to patients in Europe within the next few months.

1 Jun 2013

New clinical practice guidelines on sleep apnea, driving risk on non-commercial drivers

The American Thoracic Society has released new clinical practice guidelines on sleep apnea, sleepiness, and driving risk on non-commercial drivers.

1 Jun 2013

R-spondin2 hormone promotes follicle development, stimulates ovary growth

MD-A newly discovered hormone produced by the eggs of human females may improve the effectiveness of current fertility treatments for women and possibly lead to entirely new treatments altogether.

31 May 2013

GLYX-13 drug induces antidepressant results without street drug side effects

GLYX-13, a molecular cousin to ketamine, induces similar antidepressant results without the street drug side effects, reported a study funded by the National Institute of Mental Health (NIMH) that was published last month in Neuropsychopharmacology.

31 May 2013

Vanda Pharmaceuticals announces submission of tasimelteon NDA to FDA

Vanda Pharmaceuticals Inc. today announced the submission of a New Drug Application to the U.S. Food and Drug Administration for tasimelteon, a circadian regulator.

31 May 2013

Ragweed allergy sublingual immunotherapy: an interview with Dr. Peter Creticos, Johns Hopkins University School of Medicine

Ragweed is a dominant seasonal allergen in North America (~26% of US and North American population is allergic to this noxious weed which pollinates from early August to early October).

31 May 2013

FDA accepts Teva Pharmaceutical's sNDA for COPAXONE

Teva Pharmaceutical Industries Ltd. announced today that the U.S. Food and Drug Administration has accepted for review the company's supplemental new drug application for COPAXONE (glatiramer acetate injection) 40mg/ 1mL, a higher concentration dose of COPAXONE that offers a less frequent three times a week dosing regimen administered subcutaneously for patients with relapsing-remitting multiple sclerosis.

31 May 2013

Whiplash therapy: an interview with Dr Williamson and Dr Williams, University of Warwick

A whiplash injury is a common soft-tissue injury that may result in neck pain and other symptoms like headaches and arm pain.

30 May 2013

Researchers develop new gene therapy to thwart potential influenza pandemic

Researchers at the Perelman School of Medicine, University of Pennsylvania have developed a new gene therapy to thwart a potential influenza pandemic. Specifically, investigators in the Gene Therapy Program, Department of Pathology and Laboratory Medicine, directed by James M. Wilson, MD, PhD, demonstrated that a single dose of an adeno-associated virus expressing a broadly neutralizing flu antibody into the nasal passages of mice and ferrets gives them complete protection and substantial reductions in flu replication when exposed to lethal strains of H5N1 and H1N1 flu virus.

30 May 2013

Pacira Pharmaceuticals reports results of EXPAREL Phase 2/3 clinical trial for TKA

Pacira Pharmaceuticals, Inc. today announced findings from the completed first part of its Phase 2/3 clinical trial assessing the use and administration of EXPAREL (bupivacaine liposome injectable suspension) as a single-dose injection femoral nerve block for total knee arthroplasty surgery.

29 May 2013

LA BioMed researchers recognized for training next generation of physicians

Carol Berkowitz, MD, and Mallory D. Witt, MD, lead researchers at the Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, received the Serge & Yvette Dadone Clinical Teaching Award in Honor of Saleh Salehmoghaddam, M.D., a peer-reviewed recognition of their "outstanding dedication, innovation, and sustained excellence in clinical and classroom teaching," according to the David Geffen School of Medicine at UCLA, which presented the awards.

29 May 2013

Efficacy News and Research

Precision Biologics reports findings from Phase I/IIA study of NPC-1C at ASCO meeting

Amgen reports encouraging results from talimogene laherparepvec phase 3 study in patients with metastatic melanoma

Phase I/II study shows safety and efficacy of VB-111 in patients with rGBM

Experts to discuss on resuscitation efforts at Euroanaesthesia

Human tumors with MET amplification respond to MET inhibitor drugs

RPCI, Jasco Pharmaceuticals partner to advance development of cancer therapy

New drug for multiple myeloma could be available within next few months in Europe

New clinical practice guidelines on sleep apnea, driving risk on non-commercial drivers

R-spondin2 hormone promotes follicle development, stimulates ovary growth

GLYX-13 drug induces antidepressant results without street drug side effects

Vanda Pharmaceuticals announces submission of tasimelteon NDA to FDA

Ragweed allergy sublingual immunotherapy: an interview with Dr. Peter Creticos, Johns Hopkins University School of Medicine

FDA accepts Teva Pharmaceutical's sNDA for COPAXONE

Whiplash therapy: an interview with Dr Williamson and Dr Williams, University of Warwick

Researchers develop new gene therapy to thwart potential influenza pandemic

Pacira Pharmaceuticals reports results of EXPAREL Phase 2/3 clinical trial for TKA

LA BioMed researchers recognized for training next generation of physicians

New approach to battle prostate cancer

Valeant Pharmaceuticals receives Complete Response Letter from FDA for efinaconazole NDA

Frutarom reports increased demand for natural ingredient targeting urinary incontinence in adults

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News